Afatinib/Cetuximab in EGFR TKI-Resistant NSCLC
The mechanism of acquired resistance to epidermal growth factor... | Download Scientific Diagram
HCC827 GR cells are resistant to gefitinib in vitro and show MET... | Download Scientific Diagram
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
Cells | Free Full-Text | Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy | HTML
MET amplification causes EGFR-TKI resistance by activating... | Download Scientific Diagram
11 Terapias dirigidas Cáncer de Pulmón
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer | Molecular Cancer Therapeutics
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
Met signaling pathway and EGF receptor tyrosine kinase inhibitor... | Download Scientific Diagram
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer | European Respiratory Society
Resistance mechanisms to osimertinib in EGFR -mutated non-small cell lung cancer | British Journal of Cancer
Resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer and strategies to overcome it | Australian Medical Student Journal
Mechanisms of osimertinib resistance and emerging treatment options - Lung Cancer
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
Frontiers | Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors | Oncology
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer | Biomarker Research | Full Text
Figure 2 from Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. | Semantic Scholar
IJMS | Free Full-Text | Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy | HTML
